Clinical and diagnostic role of autoantibodies to gangliosides of peripheral nerves: literature review and own expirience

The study of anti-glycolipid antibodies has become available to general practice in Russia. Indications for determining antibodies to gangliosides
are Guillain–Barré syndrome, Miller Fisher syndrome, Bickerstaff’s encephalitis, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy. The indication for measuring anti-MAG antibodies is IgM paraprotein-associated polyneuropathy. These immunological tests must be included in diagnostic protocols if the listed dysimmune diseases are suspected.

1. Latov N. Antibodies t o glycoconjugates in neuropathy and motor-neuron disease. Proc Brain Res 1994;101:295–303.

2. Chassande B., Leger J.M., Younes-Chennoufi et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 1998;21:55–62.

3. Kornberg A.J., Pestronk A. Chronic motor neuropathies: diagnosis, therapy, and pathogenesis. Ann Neurol 1995;37 Suppl 1:43–50.

4. Ilyas A.A., Quarles R.H., Dalakas M.C. et al. Monoclonal IgM in patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Ann Neurol 1985;18:655–9.

5. Willison H.J., O’Learly, Veitch J. et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001;24:1968–77.

6. Ilyas A.A., Willison H.J., Quarles R.H. et al. Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann Neurol 1988;23:440–7.

7. Svennerholm L. Designation and schematic structure of gangliosides and allied glycosphingolipids. Prog Brain Res 1994;101:11–4.

8. Weller M., Stevens A., Sommer N. et al. Ganglioside antibodies: a lack of diagnostic specificity and clinical utility? J Neurol 1992;239:455–59.

9. Yuki N., Yoshino H., Sato S., Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990;40:1900–2.

10. Chiba A., Kusunoki S., Obata H. et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911–7.

11. Gong Y., Lunn M.P., Heffer-Lauc M. et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. J Periph Nerv Syst 2001;6:42.

12. Corbo M., Quattrini A., Latov N., Hays A.P. Localisation of GM1 and Gal(beta1-3)GalNAc antigenic determinants in peripheral nerve. Neurology 1993;43:809–14.

13. O’Hanlon G.M., Paterson G.J., Veitch J. et al. Mapping immunoreactive epitopes in the the human peripheral nervous system using human monoclonal anti-GM1 ganglioside antibodies. Acta Neuropathol (Berl) 1998;95:605–16.

14. Zielasek J., Ritter G., Magi S. et al. A comparative trial of anti-glyoconjugate antibody assays: IgM antibodies to GM1. J Neurol 1994;241:475–80.

15. Willison H., Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002;125:2591–625.

16. Bansal A.S., Abdul-Karim B., Malik R.A. et al. IgM ganglioside GM1 antibodies in patients with autoimmune disease or neuropathy, and controls. J Clin Pathol 1994;47:300–2.

17. Nobile-Orazio E., Galia F., Terenghi F. et al. How useful are anti-neural IgM antibodies in the diagnosis of chronic immunemediated neuropathies? J Neurol Sci 2008;266:156–63.

18. Irie S., Saito T., Kanazawa N. et al. Relationship between Anti-ganglioside antibodies and clinical characteristics of Guillain-Barre syndrome. – Int Med 1997;36(9):607–12.

19. Kanzaki M., Kaida K., Ueda M. et al. Ganglioside complex containing GQ1b as targets in Miller Fisher and Guillain-Barre syndromes. J Neurol Neurosurg Psychiatry 2008;79:1148–52.

20. Fredman P., Vedeler C.A., Nyland H. et al. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulfatide of peripheral nerve myelin. J Neurol 1991;238:75–9.

21. Yuki N., Tagawa Y., Handa S. Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1996;70:1–6.

22. Yako K., Kusunoki S., Kanazawa I. Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barre syndrome. J Neurol Sci 1999;168:85–9.

23. Susuki K., Yuki N., Hirata K., Kuwabara S. Fine specificities of anti-LM1 IgG antibodies in Guillain-Barre syndrome. J Neurol Sci 2002;195:145–8.

24. Jacobs B.C., van Doorn P.A., Groeneveld J.H. et al. Cytomegalovirus infection and anti-GM2 antibodies in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1997;62:641–3.

25. Walsh F.S., Cronin M., Koblar S. et al. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barre syndrome. J Neuroimmunol 1991;34:43–51.

26. Kornberg A.J., Pestronk A., Bieser K. et al. The clinical correlates of high-titer IgG anti- GM1 antiboies. Ann Neurol 1994;35:234–7.

27. Rees J.H., Gregson N.A., Hughes R.A. Anti-ganglioside GM1 antibodies in Guillain- Barre syndrome and their relationship to Campylobacter infection. Ann Neurol 1995;38: 809–16.

28. Jacobs B.C., van Doorn P.A., Schmitz P.I. et al. Campylobacter jejuni infections and anti- GM1 antibodies in Guillain-Barre syndrome. Ann Neurol 1996;40:181–7.

29. Hadden R.D., Cornblath D.R., Hughes R.A. et al. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Ann Neurol 1998;44:780–8.

30. Kuwabara S., Asahina M., Koga M. et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome. Ann Neurol 1998;44:202–8.

31. Kuwabara S., Ogawara K., Mizobuchi K. et al. Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barre syndrome with antiganglioside antibodies. J Neurol Neurosurg Psychiatry 2000;68:191–5.

32. Yuki N., Ang C.W., Koga M. et al. Clinical features and response to treatment in Guillain-Barre syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 2000;47:314–21.

33. Yuki N., Yamada M., Sato S. et al. Association of IgG anti-GD1a antibody with severe Guillain-Barre syndrome. Muscle Nerve 1993;16:642–7.

34. Kusunoki S., Iwamori M., Chiba A. et al. GM1b ia a new member of antigen for serum antibody in Guillain-Barre syndrome. Neurology 1996;47:237–42.

35. Ho T.W., Willison H.J., Nachamkin I. et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. – Ann Neurol 1999;45:168–73.

36. Hao Q., Saida T., Yoshino H. et al. Anti-GalNAc-GD1a antibody-associated Guillain- Barre syndrome with predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann Neurol 1999;45:758–68.

37. Griffin J.W., Li C.Y., Ho T.W. et al. Pathology of the motor-sensory axonal Guillan-Barre syndrome. Ann Neurol 1996;39:17–28.

38. Yuki N., Kuwabara S., Koga M., Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci 1999;168:121–6.

39. Kusunoki S., Chiba A., Hitoshi S. et al. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 1995;18:409–13.

40. Quarles R.H. The spectrum and pathogenesis of antibody-mediated neuropathies. Neuroscientist 1997;3:195–204.

41. Carpo M., Pedotti R., Lolli F. et al. Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy. J Neurol Sci 1998;155:186–91.

42. Paprounas K. Anti-GQ1b ganglioside antibody in peripheral nervous system disorders. Arch Neurol 2004;16:1013–16.

43. Notturno F., Capolare C., Uncini A. Acute sensory ataxic neuropathy with antibodies to GD1b gangliosides and prompt recovery. Muscle Nerve 2008;37:265–8.

44. Yuki N., Taki T., Kasama T. et al. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178:1771–5.

45. Ang C.W., Endtz H.P., Jacobs B.C. et al. Campylobacter jejuni lipopolysaccharides from Guillain-Barre syndrome patients induce IgG anti-GM1 antibodies in rabbits. J neroimmunol 2000;104:133–8.

46. Prendergast M.M., Lastovica A.J., Moran A.P. Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barre syndrome exhibit mimicry of GM1 ganglioside. Infect Immun 1998;66:3649–55.

47. Takano H., Yuki N. Fisher’s syndrome associated with chickenpox and anti0GQ1b antibody [letter]. J Neurol 1995;242:255–6.

48. Yuki N., Taki T., Takahashi M. et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher’s syndrome. Ann Neurol 1994;36:791–3.

49. Jacobs B.C., Hazenberg M.P., van Doorn P.A. et al. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain- Barre or Miller Fisher syndrome. J Infect Dis 1997;175:729–33.

50. Goodyear C.S., O’Hanlon G.M., Plomp J.J. et al. Monoclonl antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999;104:697–708.

51. Yuki N., Tagawa Y. Acute cytomegalovirus infection and IgM anti-GM2 antibody. J Neurol Sci 1998;154:14–7.

52. Chiba A., Kusunoki S., Obata H. et al. Ganglioside composition of the human cranial nerves, with specific reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997;745:32–6.

53. Ang C.W., Jacobs B.C., Brandenburg A.H. et al. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barre syndrome. – Neurology 2000;54:1453–8.

54. Kusunoki S., Tagawa H., Kanazawa I. Infection by Mycoplasma pneumonia anduces serum antibody against Gal-C [letter]. Muscle Nerve 1996;19:257–8.

55. Kitazawa K., Tagawa Y., Honda A., Yuki N. Guillain-Barre syndrome associated with IgG anti-GM1b antibody subsequent to Mycoplasma pneumonia infection. J Neurol Sci 1998;156:99–101.

56. Mori M., Kuwabara S., Miyake M. et al. Haemophilus influenzae infection and Guillain-Barre syndrome. Brain 2000;123:2171–8.

57. Koga M., Yuki N., Tai T. et al. Miller Fisher syndrome and Haemophilus influenza infection. Neurology 2001;57:686–91.

58. Пирадов М.А., Супонева Н.А. Синдром Гийена–Барре: клиника, диагностика и лечение. Руководство для врачей. М.: МЕД-ПРЕСС, 2011.

59. Супонева Н.А., Пирадов М.А. Внутривенная иммунотерапия в неврологии. М.: Горячая линия – Телеком, 2013.

60. Супонева Н.А., Пирадов М.А., Никитин С.С. и др. Патогенетическая и прогностическая роль аутоантител к ганглиозидам периферических нервов при синдроме Гийена–Барре. Анн клин и экспер неврологии, 2013;1:4–12.

61. Bollensen E., Steck A.J., Schachner M. Reactivity with peripheral myelin glycoprotein P0 in serum from patients with monoclonal IgM gammopathy and polyneuropathy. Neurology 1988;38:1266–70.

62. Клинические рекомендации по неврологии Европейской ассоциации неврологических сообществ. Пер. под ред. проф.С.С. Никитина. М.: АБВ-пресс, 2012.

63. Willison H.J., O’Hanlon G.M., Paterson G. et al. A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene. J Clin Invest 1996;97:1155–64.

64. Nobile-Orasio E., Manfredini E., Carpo M. et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994;36:416–24.

65. Freddo L., Yu R.K., Latov N. et al. Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology 1986;36:454–8.

66. Kuwahara M., Suzuki S., Takada K., Kusunoki S. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronicinflamm atory demyelinating polyneuropathy. J Neuroimmunol. 2011;239(1–2):87–90.

67. Remiche G., Kentos A., Mavroudakis N. Distal acquired demyelinating symmetric neuropathy associated with anti-GM1 antibodies: is this a CIDP variant? Acta Neurol Belg 2010;110(1):103–6.

68. Шевченко А.В. Хронические воспалительные демиелинизирующие полиневропатии у детей (клиника, диагностика, дифференциальная диагностика). Автореф. дис. … канд. мед. наук. М., 2007.

69. Pestronk A., Cornblath D.R., Ilyas A.A. et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73–8.

70. Van Schaik I.N., Bossuyt P.M., Brand A., Vermeulen M. Diagnostic value of GM1 antibodies in motor-neuron disorders and neuropathies: a meta-analysis. Neurology 1995;45:1570–7.

71. O’Hanlon G.M., Veitch J., Gallardo E. et al. Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies. Autoimmunity 2000;32:133–44.

72. Jacobs B.C., Rothbarth P.H., van der Meche et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a casecontrol study. Neurology 1998;51:1110–5.

73. Ахмеджанова Л.Т. Клинико-иммунологическая характеристика хронических демиелинизирующих полиневропатий. Автореф. дис. … канд. мед. наук. М., 2008.

74. Leger J.M., Chassande B., Musset L. et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a doubleblind, placebo-controlled study. Brain 2001;124:145–53.